Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis.
Armin RashidiMaryam EbadiTauseef Ur RehmanHeba ElhusseiniDavid KazadiHossam HalaweishMohammad Haneef KhanAndrea HoeschenQing CaoXianghua LuoAmanda J KabageSharon LopezSivapriya RamamoorthyShernan G HoltanDaniel J WeisdorfAlexander KhorutsChristopher M StaleyPublished in: Cancer research communications (2024)
Post-FMT expansion of Faecalibacterium, associated with donor microbiota engraftment, predicted a higher risk for aGVHD in alloHCT recipients. Although Faecalibacterium is a commensal genus with gut-protective and anti-inflammatory properties under homeostatic conditions, our findings suggest that it may become pathogenic in the setting of FMT after alloHCT. Our results support a future trial with precision engineering of the FMT product used as GVHD prophylaxis after alloHCT.
Keyphrases
- study protocol
- phase iii
- anti inflammatory
- phase ii
- clinical trial
- allogeneic hematopoietic stem cell transplantation
- liver failure
- genome wide
- respiratory failure
- current status
- randomized controlled trial
- drug induced
- dna methylation
- gene expression
- acute myeloid leukemia
- kidney transplantation
- bone marrow
- double blind
- hematopoietic stem cell